Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOSIG TECHNOLOGIES, INC.

(BSGM)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
0.4166 USD   -5.32%
11/30Biosig Technologies, Inc. : Termination of a Material Definitive Agreement (form 8-K)
AQ
11/29Biosig Technologies : Failure to Satisfy Listing Rule - Form 8-K
PU
11/29Biosig Technologies, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BioSig Technologies Expands Intellectual Property Portfolio

06/03/2020 | 11:46am EST

Westport, CT, June 03, 2020 (GLOBE NEWSWIRE) --

  • U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System
  • Five patent applications filed by ViralClear Pharmaceuticals, Inc., covering its orally administered broad-spectrum anti-viral solution for the treatment of COVID-19

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,645,017 titled “Systems, Apparatus and Methods for Conveying Biomedical Signals between a Patient and Monitoring and Treatment Devices,” which is intended to broadly protect the Company’s flagship product – the PURE EP(tm) System. 

The claims address foundational systems and devices which help with the recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures for conditioning cardiac (e.g., ECG and intercardiac) and other physiologic signals, specifically to clearly define and record low-amplitude, low-frequency information, which may be acquired during ablation and other similar large-signal perturbations, such as pacing and stimulation, without the presence of electrical noise.

“This patent reinforces the continued protection of our PURE EP(tm) System designed to enable electrophysiologists to achieve clear visualization of cardiac signals with high fidelity and low electrical noise during ablation procedures, which we believe may lead to improved success rates for AF procedures,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. “We continue to grow our intellectual property portfolio, expanding our first mover advantage in the electrophysiology digital signal processing and analysis space with our innovative platform.” 

BioSig also announced that its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc, has recently filed five new provisional patent applications of its own over the last two months with claims directed to methods of treating or preventing an infectious disease caused by a coronavirus in a human or animal by administering merimepodib, a broad-spectrum anti-viral. The patents also address methods of inhibiting coronavirus replication in a human or animal by administering merimepodib as a single agent or in combination with other therapeutic agents, e.g., antiviral agents, immune modulators, etc., such as remdesivir, as well as novel oral and IV drug formulations for merimepodib administration.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About Merimepodib (MMPD)
Merimepodib, a broad-spectrum anti-viral candidate, has demonstrated strong activity against COVID-19 in cell cultures in laboratory testing.  Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials conducted (including 315 chronic hepatitis C patients, 24 psoriasis patients, and 98 healthy volunteers) and an extensive preclinical safety package completed.

A manuscript titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

About ViralClear
BioSig’s subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against COVID-19 in cell cultures. Merimepodib has been previously studied in 12 clinical trials, including 5 in patients with hepatitis C (1 Phase 1b, 1 Phase 2, 2 Phase 2a, and 1 Phase 2b), 1 in patients with psoriasis (Phase 2), and six in healthy volunteers (Phase I).

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

Primary Logo


ę GlobeNewswire 2020
All news about BIOSIG TECHNOLOGIES, INC.
11/30Biosig Technologies, Inc. : Termination of a Material Definitive Agreement (form 8-K)
AQ
11/29Biosig Technologies : Failure to Satisfy Listing Rule - Form 8-K
PU
11/29Biosig Technologies, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
11/21Biosig Technologies, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
11/18BioSig Technologies, Inc. announced that it has received $1.452002 million in funding
CI
11/14BioSig Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
10/26Biosig Technologies, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
10/26Biosig Technologies, Inc. : Shareholder Director Nominations (form 8-K)
AQ
10/24Biosig Technologies, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/24BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applic..
CI
More news
Financials (USD)
Sales 2022 0,82 M - -
Net income 2022 -26,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,69x
Yield 2022 -
Capitalization 21,5 M 21,5 M -
Capi. / Sales 2022 26,1x
Capi. / Sales 2023 3,49x
Nbr of Employees 50
Free-Float 88,9%
Chart BIOSIG TECHNOLOGIES, INC.
Duration : Period :
BioSig Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOSIG TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,42 $
Average target price 3,17 $
Spread / Average Target 660%
EPS Revisions
Managers and Directors
Kenneth L. Londoner Executive Chairman & Chief Executive Officer
Steven Chaussy Chief Financial Officer
Budimir S. Drakulic Chief Scientist
Zachary Koch Clinical Director
John Sieckhaus Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOSIG TECHNOLOGIES, INC.-81.32%21
THERMO FISHER SCIENTIFIC-15.62%220 754
DANAHER CORPORATION-16.65%199 032
INTUITIVE SURGICAL, INC.-23.60%95 552
BOSTON SCIENTIFIC CORPORATION8.57%64 841
SIEMENS HEALTHINEERS AG-21.63%58 421